VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Friday. The firm issued a sell rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Thursday, March 20th.

VolitionRx Stock Up 4.2 %

VolitionRx stock opened at $0.55 on Friday. The business has a 50 day moving average price of $0.59 and a two-hundred day moving average price of $0.64. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.02. The stock has a market cap of $50.97 million, a price-to-earnings ratio of -1.53 and a beta of 1.09.

Insider Buying and Selling

In related news, CEO Cameron John Reynolds purchased 181,818 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average price of $0.55 per share, with a total value of $99,999.90. Following the purchase, the chief executive officer now directly owns 2,299,222 shares in the company, valued at $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Two Sigma Securities LLC bought a new stake in VolitionRx during the fourth quarter worth about $29,000. Northern Trust Corp increased its holdings in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. raised its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of VolitionRx in the 4th quarter worth approximately $36,000. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.